RFK Jr.'s cuts to vaccine funding threaten pandemic preparedness, Canadian health experts warn
U.S. Health Secretary Robert F. Kennedy Jr. announced on Tuesday that 22 mRNA-based projects will be halted and no new projects will be green lit. He claimed data show these vaccines 'fail to protect effectively against upper respiratory infections like COVID and flu.'
Vaccine specialists on both sides of the border have stressed that mRNA technology is safe and effective, in addition to being a necessary tool to prevent future pandemics. While mRNA research will continue elsewhere, Canadian experts said the U.S. cuts will be felt across the global scientific community.
Kennedy's firing of U.S. immunization committee is worrisome, Canadian scientists say
Pieter Cullis, a biochemist at the University of British Columbia whose discoveries with lipid membranes ultimately provided the delivery system for COVID-19 vaccines, said the decision is 'bewildering.'
'This is the most promising technology we have for diseases – rare diseases, infectious diseases, cancer, cardiovascular, you name it,' said Dr. Cullis. 'It's one of the most successful innovations in medicine in the last 10 years or longer and they're completely ignoring it.'
Mr. Kennedy, a long-time vaccine skeptic, has made a number of changes to vaccine programming in the U.S. Earlier this year, he pulled back recommendations on COVID vaccinations for pregnant women and children. He also turfed the U.S. panel responsible for making vaccine recommendations.
The Health Secretary said on Tuesday that funding will be shifted toward 'broader vaccine platforms that remain effective even as viruses mutate.' One of the earlier cuts at the U.S. Department of Health and Human Services, or HHS, was Moderna's contract to develop a human vaccine for bird flu – a disease of increasing concern.
Allison McGeer, an infectious-diseases specialist at Mount Sinai Hospital in Toronto, said there is no other word to describe the recent U.S. cuts than 'nonsense.'
She stressed that the production and distribution of COVID-19 vaccines, which have saved countless lives, was substantially a U.S. initiative and one that greatly benefitted Canada. But Canada can no longer rely on this partnership for pandemic preparedness.
'There's just no doubt that this puts an enormous hole in the work that's going on and, even if everybody else in the world tries to step in, it's going to be hard to make up this loss,' she said.
Dr. McGeer said there is a lot of important work being undertaken in Canada on mRNA technology and it could be expanded. But while Canada feels the impact of tariffs imposed by Mr. Trump, she's worried investments in science will decrease.
'I'm undeniably very anxious that we will lose ground in Canada because we're looking for funding for prevention. Funding for prevention is always hard and even harder in our current economic situation,' said Dr. McGeer.
Mr. Kennedy's latest comments on vaccines are also fuelling vaccine hesitancy and opposition, said Lynora Saxinger, an infectious-diseases specialist at the University of Alberta. She said the cuts signal the 'triumph of disinformation over science.'
Dr. Saxinger said there is already a proportion of the Canadian population that aligns with the U.S. Her concern, however, is for people who are on the fence and could fall victim to disinformation by consuming it frequently.
'The fact that it's being elevated by the secretary of HHS does make it more likely that people who might not otherwise be paying a lot of attention will see more and more about this and it will undermine their trust in vaccines as well,' she said.
'We're reaching a point now where I think anything coming out of the U.S. that has to do with science and human health, you have to doubt it.'
The Infectious Diseases Society of America, in a statement on Wednesday, said the recent cuts 'are deeply concerning and reflect an alarming pattern of the Administration's efforts to curtail vaccine research and sow unfounded doubt in vaccine safety and effectiveness.'
With a file from the Associated Press
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
17 minutes ago
- Globe and Mail
SelectQuote to Release Fiscal Fourth Quarter and Full Year 2025 Earnings on August 21
SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its fourth quarter and full year 2025 financial results before market open on Thursday, August 21, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (August 21, 2025) at 8:30 am ET to discuss the results. To register for this conference call, please use this link: After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website or via this link. About SelectQuote: Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care. With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select, which proactively connects consumers with a wide breadth of healthcare services supporting their needs.
Globe and Mail
17 minutes ago
- Globe and Mail
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company's guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, or 31.4% in constant currency U.S. Omnipod revenue of $453.2 million, up 28.7% International Omnipod revenue of $185.8 million, up 45.0%, or 38.8% in constant currency Drug Delivery revenue of $10.2 million Gross margin of 69.7%, up 190 basis points over prior year Operating income of $121.1 million, or 18.7% of revenue, up 750 basis points over prior year Adjusted operating income 1 of $115.8 million, or 17.8% of revenue, up 670 basis points over prior year Net income of $22.5 million, or $0.32 per diluted share, compared with $188.6 million, or $2.59 per diluted share in prior year Adjusted net income 1 of $83.7 million, or $1.17 per diluted share, compared with $38.3 million, or $0.55 per diluted share in prior year Adjusted EBITDA 1 of $157.5 million, or 24.3% of revenue, up 570 basis points over prior year Recent Strategic Highlights: Announced Omnipod 5 App for iPhone compatible with Dexcom's G7 Continuous Glucose Monitor (CGM) sensor fully available in the U.S. Integrated Omnipod 5 with Dexcom's G7 CGM sensor in Germany and Abbott's FreeStyle Libre 2 Plus CGM sensor in Australia Collaborated with Marvel to launch comic book hero, Dyasonic, who lives with type 1 diabetes Presented strong clinical data at the American Diabetes Association (ADA) Scientific Session from the Company's SECURE-T2D and RADIANT trials, as well as real-world evidence of improved glycemic outcomes from more than 23,000 people with type 2 diabetes using Omnipod 5 in the U.S. Initiated redemption for remaining $380 million principal of convertible notes and refinanced Term Loan B Advanced sustainability across the Company, as detailed in Insulet's 2024 Sustainability Report 2 'We delivered robust second quarter results, reflecting our team's strong performance and the compelling impact and appeal of Omnipod 5 for people living with diabetes,' said Ashley McEvoy, President and CEO. 'Engaging with our partners, physicians, investors, and Podders this quarter has demonstrated our opportunity to revolutionize diabetes management and the value of our unique position at the nexus of consumer health, medtech, and health tech. As we scale the Company, I'm confident in our ability to grow and create value for all our stakeholders in the future.' 2025 Outlook: For the quarter ending September 30, 2025 and year ending December 31, 2025, the Company is providing the following guidance (revenue in constant currency): Conference Call: Insulet will host a conference call at 8:00 a.m. (Eastern Time) on August 7, 2025 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company's website at 'Events and Presentations,' and will be archived for future reference. The live call may also be accessed by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or Non-GAAP Measures: The Company uses the following non-GAAP financial measures: Constant currency revenue growth, which represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents constant currency revenue growth because management believes it provides meaningful information regarding the Company's results on a consistent and comparable basis. Management uses this non-GAAP financial measure, in addition to financial measures in accordance with generally accepted accounting principles in the United States (GAAP), to evaluate the Company's operating results. It is also one of the performance metrics that determines management incentive compensation. Adjusted gross margin, adjusted gross margin as a percentage of revenue, adjusted operating income, adjusted operating income as a percentage of revenue, adjusted net income, and adjusted diluted earnings per share exclude the impact of certain significant transactions or events, such as legal settlements, medical device corrections, gains (losses) on investments and loss on extinguishment of debt, that affect the period-to-period comparability of the Company's performance, as applicable. Adjusted EBITDA, which represents net income plus net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense and other significant transactions or events, such as legal settlements, medical device corrections, gains (losses) on investments and loss on extinguishment of debt, which affect the period-to-period comparability of the Company's performance, as applicable, and adjusted EBITDA as a percentage of revenue. Free cash flow, which is defined as net cash provided by operating activities less capital expenditures. Insulet presents the above non-GAAP financial measures because management uses them as supplemental measures in assessing the Company's performance, and the Company believes they are helpful to investors and other interested parties as measures of comparative performance from period to period. They also are commonly used measures in determining business value, and the Company uses them internally to report results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with GAAP. Furthermore, the Company's definition of these non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, Insulet strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. Forward-Looking Statement: This press release contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, assumptions and estimates and are not intended to be a guarantee of future events or performance. If management's underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by the forward-looking statements. Risks and uncertainties include, but are not limited to our dependence on a principal product platform; the impact of competitive products, technological change and product innovation; our ability to maintain an effective sales force and expand our distribution network; our ability to maintain and grow our customer base; our ability to scale the business to support revenue growth; our ability to secure and retain adequate coverage or reimbursement from third-party payors; the impact of healthcare reform laws; our ability to design, develop, manufacture and commercialize future products; unfavorable results of clinical studies, including issues with third parties conducting any studies, or future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable; our ability to protect our intellectual property and other proprietary rights; potential conflicts with the intellectual property of third parties; our inability to maintain or enter into new license or other agreements with respect to continuous glucose monitors, data management systems or other rights necessary to sell our current product and/or commercialize future products; worldwide macroeconomic and geopolitical uncertainty, as well as risks associated with public health crises and pandemics, including government actions and restrictive measures implemented in response, supply chain disruptions, delays in clinical trials, and other impacts to the business, our customers, suppliers, and employees; international regulatory, commercial and logistics business risks, including the implementation of tariffs; the potential violation of anti-bribery/anti-corruption laws; the concentration of manufacturing operations and storage of inventory in a limited number of locations; supply problems or price fluctuations with sole source or third-party suppliers on which we are dependent; failure to retain key suppliers; challenges to the future development of our non-insulin drug delivery product line; our failure or that of our contract manufacturer or component suppliers to comply with the U.S. Food and Drug Administration's quality system regulations or other manufacturing difficulties; extensive government regulation applicable to medical devices, as well as complex and evolving privacy and data protection laws; our use of artificial intelligence tools; adverse regulatory or legal actions relating to current or future Omnipod products; potential adverse impacts resulting from a recall, or discovery of serious safety issues, or product liability lawsuits relating to off-label use; breaches or failures of our product or information technology systems, including by cyberattack; our ability to attract, motivate, and retain key personnel; risks associated with potential future acquisitions or investments in new businesses; ability to raise additional funds on acceptable terms or at all; the volatility of the trading price of our common stock; and changes in tax laws or exposure to significant tax liabilities. For a further list and description of these and other important risks and uncertainties that may affect the Company's future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which the Company may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q the Company has filed or will file hereafter. Any forward-looking statement made in this release speaks only as of the date of this release. Insulet does not undertake to update any forward-looking statement, other than as required by law. ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. Three Months Ended June 30, Six Months Ended June 30, (dollars in millions, except per share data) 2025 2024 2025 2024 Revenue $ 649.1 $ 488.5 $ 1,218.1 $ 930.2 Cost of revenue 196.9 157.6 356.8 292.5 Gross profit 452.2 330.9 861.3 637.7 Research and development expenses 73.4 53.9 133.0 104.1 Selling, general and administrative expenses 257.7 222.5 518.4 422.2 Operating income 121.1 54.5 209.9 111.5 Interest expense, net (9.5 ) (1.7 ) (8.5 ) (3.0 ) Loss on extinguishment of debt (84.4 ) — (123.9 ) — Other income (expense), net 1.3 (1.8 ) (0.9 ) (2.5 ) Income before income taxes 28.4 51.1 76.5 106.0 Income tax (expense) benefit (5.9 ) 137.5 (18.6 ) 134.1 Net income $ 22.5 $ 188.6 $ 57.9 $ 240.1 Earnings per share: Basic $ 0.32 $ 2.69 $ 0.82 $ 3.43 Diluted $ 0.32 $ 2.59 $ 0.82 $ 3.32 Weighted-average number of common shares outstanding (in thousands): Basic 70,389 70,062 70,330 70,010 Diluted 70,652 73,802 70,641 73,771 Three Months Ended June 30, Six Months Ended June 30, (in millions) 2025 2024 2025 2024 Net income $ 22.5 $ 188.6 $ 57.9 $ 240.1 Add back interest expense, net of tax attributable to assumed conversion of convertible notes — 2.5 — 4.9 Net income, diluted $ 22.5 $ 191.1 $ 57.9 $ 245.0 Note: May not add or recalculate due to rounding. INSULET CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (dollars in millions) June 30, 2025 December 31, 2024 ASSETS Cash and cash equivalents $ 1,121.6 $ 953.4 Accounts receivable, net 444.5 365.5 Inventories 446.9 430.4 Prepaid expenses and other current assets 266.7 142.0 Total current assets 2,279.7 1,891.3 Property, plant and equipment, net 720.4 723.1 Other intangible assets, net 102.3 98.5 Goodwill 51.7 51.5 Other assets 315.1 323.3 Total assets $ 3,469.2 $ 3,087.7 LIABILITIES AND STOCKHOLDERS' EQUITY Accounts payable $ 96.1 $ 19.8 Accrued expenses and other current liabilities 453.4 424.9 Current portion of long-term debt 460.7 83.8 Total current liabilities 1,010.1 528.4 Long-term debt, net 939.0 1,296.1 Other liabilities 57.1 51.7 Total liabilities 2,006.3 1,876.1 Stockholders' equity 1,462.9 1,211.6 Total liabilities and stockholders' equity $ 3,469.2 $ 3,087.7 Note: May not add due to rounding. INSULET CORPORATION Three Months Ended June 30, (dollars in millions) 2025 2024 Percent Change Currency Impact Constant Currency U.S. $ 453.2 $ 352.3 28.7 % — % 28.7 % International 185.8 128.2 45.0 % 6.2 % 38.8 % Total Omnipod Products 639.0 480.4 33.0 % 1.6 % 31.4 % Drug Delivery 10.2 8.1 25.7 % — % 25.7 % Total $ 649.1 $ 488.5 32.9 % 1.6 % 31.3 % Six Months Ended June 30, (dollars in millions) 2025 2024 Percent Change Currency Impact Constant Currency U.S. $ 854.9 $ 670.0 27.6 % — % 27.6 % International 338.1 243.4 38.9 % 1.4 % 37.5 % Total Omnipod Products 1,193.0 913.4 30.6 % 0.4 % 30.2 % Drug Delivery 25.1 16.8 49.2 % — % 49.2 % Total $ 1,218.1 $ 930.2 30.9 % 0.4 % 30.6 % Note: Columns and rows may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. ADJUSTED OPERATING INCOME, NET INCOME & DILUTED EPS Three Months Ended June 30, 2025 (in millions, except per share data) Operating Income Percent of Revenue Income before Income Taxes Net Income (4) Net Income, Diluted Diluted Earnings per Share Effective Tax Rates GAAP $ 121.1 18.7 % $ 28.4 $ 22.5 $ 22.5 $ 0.32 20.8 % CEO transition costs (1) (5.3 ) (5.3 ) (5.5 ) (5.5 ) $ (0.08 ) Loss on extinguishment of debt (2) — 84.4 84.1 84.1 $ 1.16 Tax matters (3) — — (17.3 ) (17.3 ) $ (0.24 ) Interest expense, net of tax attributable to assumed conversion of convertible notes — — — 1.2 $ 0.02 Non-GAAP $ 115.8 17.8 % $ 107.5 $ 83.7 $ 85.0 $ 1.17 22.1 % Six Months Ended June 30, 2025 (in millions, except per share data) Operating Income Percent of Revenue Income before Income Taxes Net Income (4) Net Income, Diluted Diluted Earnings per Share Effective Tax Rates GAAP $ 209.9 17.2 % $ 76.5 $ 57.9 $ 57.9 $ 0.82 24.3 % CEO transition costs (1) (5.3 ) (5.3 ) (5.5 ) (5.5 ) $ (0.07 ) Loss on investments (5) 4.7 7.5 5.8 5.8 $ 0.08 Loss on extinguishment of debt (2) — 123.9 123.0 123.0 $ 1.68 Tax matters (3) — — (23.8 ) (23.8 ) $ (0.32 ) Interest expense, net of tax attributable to assumed conversion of convertible notes — — — 2.9 $ 0.04 Non-GAAP $ 209.2 17.2 % $ 202.6 $ 157.4 $ 160.3 $ 2.19 22.3 % (1) Relates to the forfeiture of equity awards by the Company's former Chief Executive Officer, net of severance benefits. (2) Relates to the repurchase of a portion of the Company's convertible debt. (3) Primarily represents consolidating effective tax rate adjustment related to non-GAAP items and excess tax benefits related to employee share-based compensation. (4) The tax effect on non-GAAP adjustments is calculated based on applicable local statutory rates. (5) Represents a provision for credit loss included in selling, general and administrative expenses related to a debt investment and an impairment included in other expense related to an equity investment. DILUTED SHARES (in thousands) Three Months Ended June 30, 2025 Six Months Ended June 30, 2025 GAAP weighted average number of common shares outstanding, diluted 70,652 70,641 Convertible notes 1,862 2,671 Non-GAAP weighted average number of common shares outstanding, diluted 72,514 73,312 Note: Columns and rows may not add due to rounding or the difference in diluted shares on a GAAP and non-GAAP basis. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. INSULET CORPORATION Three Months Ended June 30, 2024 (dollars in millions) Income before Income Taxes Net Income (3) Net Income, Diluted Diluted Earnings per Share Effective Tax Rate GAAP $ 51.1 $ 188.6 $ 191.1 $ 2.59 (269.3 )% Loss on investments (1) 1.8 1.4 1.4 0.02 Tax matters (2) — (151.7 ) (151.7 ) (2.06 ) Non-GAAP $ 52.8 $ 38.3 $ 40.8 $ 0.55 27.6 % Six Months Ended June 30, 2024 (dollars in millions) Income before Income Taxes Net Income (3) Net Income, Diluted Diluted Earnings per Share Effective Tax Rate GAAP $ 106.0 $ 240.1 $ 245.0 $ 3.32 (126.6 )% Loss on investments (1) 1.8 1.4 1.4 0.02 Tax matters (2) — (158.3 ) (158.3 ) (2.15 ) Non-GAAP $ 107.7 $ 83.2 $ 88.2 $ 1.19 22.8 % (1) Represents non-operating loss resulting from the fair value adjustment of a strategic debt investment. (2) Includes tax benefit of $146.9 million and $153.5 million for the three and six months ended June 30, 2024, respectively, resulting from the release of the majority of the Company's income tax valuation allowance. Both periods also include a $4.8 million tax benefit related to a research and development tax credit recovery project for tax years 2017 through 2021. (3) The tax effect on non-GAAP adjustments is calculated based on applicable local statutory rates. Note: Columns and rows may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. ADJUSTED EBITDA Three Months Ended June 30, Six Months Ended June 30, (dollars in millions) 2025 Percent of Revenue 2024 Percent of Revenue 2025 Percent of Revenue 2024 Percent of Revenue Net income $ 22.5 3.5 % $ 188.6 38.6 % $ 57.9 4.8 % $ 240.1 25.8 % Interest expense, net 9.5 1.7 8.5 3.0 Income tax expense (benefit) 5.9 (137.5 ) 18.6 (134.1 ) Depreciation and amortization 22.3 19.3 44.0 38.0 Stock-based compensation expense (1) 7.5 17.0 25.7 31.2 CEO transition (2) 5.4 — 5.4 — Loss on extinguishment of debt (3) 84.4 — 123.9 — Loss on investments (4) — 1.8 7.5 1.8 Adjusted EBITDA $ 157.5 24.3 % $ 90.9 18.6 % $ 291.5 23.9 % $ 180.0 19.4 % (1) Amounts for both the three and six months ended June 30, 2025 includes $10.8 million reversal of stock-based compensation expense associated with the departure of the Company's former Chief Executive Officer (CEO). (2) Represents severance expense related to the departure of the Company's former CEO. (3) Relates to the repurchase of a portion of the Company's convertible debt. (4) Represents losses associated with debt and equity investments. FREE CASH FLOW (in millions) Six Months Ended June 30, 2025 Net cash provided by operating activities $ 260.3 Capital expenditures (30.9 ) Free cash flow $ 229.4 Note: Columns may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. INSULET CORPORATION Year Ending December 31, 2025 U.S. Omnipod 22% - 25% —% 22% - 25% International Omnipod 37% - 40% 3% 34% - 37% Total Omnipod 26% - 29% 1% 25% - 28% Drug Delivery (30)% - (25)% —% (30)% - (25)% Total 25% - 28% 1% 24% - 27% Three Months Ended September 30, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 21% - 24% —% 21% - 24% International Omnipod 36% - 39% 3% 33% - 36% Total Omnipod 25% - 28% 1% 24% - 27% Drug Delivery (80)% - (75)% —% (80)% - (75)% Total 23% - 26% 1% 22% - 25%
Globe and Mail
17 minutes ago
- Globe and Mail
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, August 12, 2025, at 4:30 p.m. ET, to discuss second quarter 2025 business and financial updates. The webcast will be available on the Investors & News section of Stoke's website at Research analysts who plan to join the call and participate in the Q&A session may register here to receive the dial-in details and a unique PIN. All other participants are invited to access the listen-only webcast by clicking here. An archived replay of the webcast will be available for at least 90 days following the event. About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit
